Expect Limited Use of IV Brexanolone (Zulresso) for Postpartum Depression

Intravenous brexanolone (Zulresso, zul-REH-soh) will make a splash as the first FDA-approved treatment for postpartum depression.

Brexanolone has a unique mechanism...it mimics the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.

Brexanolone is given as a single 60-hour infusion. It starts to improve depression symptoms 24 to 48 hours after starting the infusion. In comparison, SSRIs take at least 1 to 2 weeks to start working.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote